Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

lopment and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of future trials will not correlate with the results of these trials and the risk that the results of future combination trials with other chemotherapeutic agents will not be consistent with the results of these trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The report, "Synthetic Biology Market by ... Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & ... Global Forecast to 2018", analyses and studies ... challenges. , Browse 99 market data tables ... and in-depth TOC of the global synthetic ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 BlueInGreen, ... Ozone Solutions, LLC (Pinnacle), and PCI, Inc., leading ... that they have been selected to provide a ... Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... patented HyDOZ® gas dissolution technology, Pinnacle ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... Sodium Ferrocyanide Industryā€¯ is a professional and in-depth ... provides Sodium ferrocyanide information, like its definition, ... as industry overview. This report covers the international ... as global (such as the US, Europe, Asia, ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... In a merging of complementary companies, Cytochroma, Inc ., ... has acquired Proventiv Therapeutics, LLC, of Madison, and the combined ... capital from Canadian and American investors. , ,Proventiv was founded ... International , which was acquired last year by Genzyme ...
... Foundry , a provider of media communications technology, will be ... and family get in touch with their loved ones serving ... Wisconsin Department of Veterans Affairs to offer Mediasite ... , ,The messages can be recorded with both audio and ...
... recent legislative setbacks, proponents of net neutrality said their ... of the United States Senate not to take up ... are included. , ,The pro-neutrality group It'sOurNet , ... to reject the telecommunications bill following a tie vote ...
Cached Biology Technology:Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO 2Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO 3Net neutrality will be back, supporters vow 2Net neutrality will be back, supporters vow 3Net neutrality will be back, supporters vow 4
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
(Date:11/7/2014)... , November 6, 2014 Leading ... for better mobile security revolutionizing online transactions.  Companies in focus ... Holdings Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... ), eBay Inc. (NASDAQ: EBAY ) and MasterCard ... NXTD and NXTDW), a biometric authentication company focused on ...
(Date:11/6/2014)... when that predator runs so fast that it essentially blinds ... the fastest creature on Earth. Some of these half-inch-long beetles ... miles per hour). The fastest human can do about five ... beetle, a person would have to hit 480 miles per ... peak speeds, everything becomes a blur. They can,t gather enough ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6The tiger beetle: Too fast to see 2
... of Iowa researchers have found the existence of a new, ... find the genetic cause, which investigators hope will increase understanding ... the Nov. 9 issue of the Archives of Ophthalmology ... area of high-resolution central vision that is needed to read ...
... , , , ... www.kornberg.com ) has converted part of an existing building (Keen ... innovative stem cell core facility for the University of California, ... , "A key project element was to ensure ...
... WASHINGTON, Dec. 10, 2009 Arup K. SenGupta, Ph.D., ... Lehigh University in Bethlehem, Pa., has been chosen to ... administered by the American Chemical Society, is given to ... improve public health through their work in the chemical ...
Cached Biology News:New inherited eye disease discovered 2Kornberg Associates | Architects Completes UC Riverside Stem Cell Core Facility Project 2
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Request Info...
Biology Products: